Bos MK, Lam SW, Motta G, Helmijr JCA, et al. Plasma ESR1 mutations and outcome to first-line paclitaxel and bevacizumab in patients with advanced ER-positive/HER2-negative breast cancer. Breast Cancer Res Treat 2023 May 25. doi: 10.1007/s10549-023-06965.
PMID: 37226020